Back to Search
Start Over
Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands
- Source :
- Breast Cancer Research and Treatment, 129(1), 229-233. SPRINGER, Breast Cancer Research and Treatment; Vol 129, Breast Cancer Research and Treatment, 129(1), 229-233. Springer, Cham, Breast Cancer Research and Treatment, Breast Cancer Research and Treatment, Springer Verlag, 2011, 129 (1), pp.229-233. ⟨10.1007/s10549-011-1451-0⟩, Breast cancer research and treatment, 129(1), 229-233. Springer
- Publication Year :
- 2011
- Publisher :
- SPRINGER, 2011.
-
Abstract
- International audience; Trastuzumab in conjunction with adjuvant chemotherapy markedly improves outcome. In the Netherlands, a national guideline was released in September 2005 stating that trastuzumab should be given in conjunction with adjuvant chemotherapy in women with HER2-positive breast cancer. Aim of this study was to identify the number of women with HER2-positive breast cancer and to evaluate the level of implementation of adjuvant trastuzumab in clinical practice nationwide. Women diagnosed with primary breast cancer between September 2005 and January 2007 were selected from the Netherlands Cancer Registry (NCR). HER2 status, adjuvant treatment and reasons to withhold trastuzumab were registered. 14,934 Breast cancer patients were diagnosed in this period of whom 1,928 (13%) had a HER2-positive tumour. Of all HER2-positive women receiving adjuvant chemotherapy, 66 (6%) did not receive trastuzumab. This percentage decreased from 10% at the time of introduction of the guideline to 4% in the study period September 2005-December 2006. Most common reasons to withhold trastuzumab were cardiovascular disease (29%) and patient refusal (21%). Of all HER2-positive patients who received adjuvant chemotherapy, 94% received trastuzumab. The implementation of trastuzumab in clinical practice was realized within 8 months after introduction of the new guideline.
- Subjects :
- Adult
Oncology
Cancer Research
medicine.medical_specialty
Receptor, ErbB-2
Adjuvant chemotherapy
IR-77770
medicine.medical_treatment
Antineoplastic Agents
Breast Neoplasms
Disease
ONCOGENE
Guideline
Antibodies, Monoclonal, Humanized
Young Adult
03 medical and health sciences
0302 clinical medicine
Breast cancer
Trastuzumab
Internal medicine
HER2
medicine
Humans
Non metastatic
030212 general & internal medicine
skin and connective tissue diseases
neoplasms
Adjuvant
Aged
Netherlands
Aged, 80 and over
business.industry
Antibodies, Monoclonal
Middle Aged
medicine.disease
3. Good health
Cancer registry
Chemotherapy, Adjuvant
HER-2
030220 oncology & carcinogenesis
Female
METIS-277775
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 01676806 and 15737217
- Volume :
- 129
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Breast Cancer Research and Treatment
- Accession number :
- edsair.doi.dedup.....5deb235f138cd2198e049943c5d96bf6